Inhibitors of protein prenylation 2000

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 12, 2000, Pages 1813-1831

  Bell, I M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cancer therapy; Farnesyltransferase; Farnesyltransferase inhibitors; Geranylgeranyltransferase; Protein prenylation; Ras oncogene

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTINEOPLASTIC AGENT; BIM 46050; CHAETOMEMIC ACID D; CP 609754; DIMETHYLALLYLTRANSFERASE; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; FENCLONINE; GEMCITABINE; GERANYLTRANSFERASE; GERANYLTRANSFERASE INHIBITOR; GLYCINAMIDE; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; L 778123; LONAFARNIB; MAGNESIUM ION; MANGANESE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; QUINOXALINE 5,8 DIONE DERIVATIVE; QUINOXALINE DERIVATIVE; RAS PROTEIN; TETRAPEPTIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC ION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG DESIGN; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; LIVER TOXICITY; MOUSE; NEUROTOXICITY; NONHUMAN; ONCOGENE RAS; PATENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRENYLATION; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

EID: 0033664419     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.12.1813     Document Type: Review

References (70)

1. Inhibitors of protein prenylation 1999
2. Ras oncogenes in human cancer: A review
3. Ras proto-oncogene activation in human malignancy
4. Harvey murine sarcoma virus p21 ras protein: Biological and biochemical significance of the cysteine nearest the carboxy terminus
5. p21 Ras is modified by a farnesyl isoprenoid
6. Inhibitors of protein farnesylation: A new approach to cancer chemotherapy
7. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
8. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
9. The farnesyl protein transferase (FPTase) inhibitor L-778, 123 in patients with solid cancers
10. Phase I clinical trial of the farneslytransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
11. Comparison of potential markers of farnesyltransferase inhibition
12. Activity of SCH66336, a tricyclic farnesyltransferase inhibitor against human tumor colony-forming units
13. Phase I and pharmacologic study of continuous daily oral SCH66336, a novel farnesyl transferase inhibitor
14. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers
15. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
16. A Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
17. Use of farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemias: Preliminary results of a Phase I trial
18. A Phase I and pharmacokinetic (PK) study of the farnesyl transferase inhibitor R115777 in combination with gemcitabine
19. Biochemical evaluation of specific geranylgeranyltransferase inhibitors
20. BMS-214662, a highly potent apoptotic farnesyltransferase inhibitor
21. Pharmacokinetics (PK) and pharmacodynamics (PD) of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
22. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
23. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
24. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol and gemcitabine
25. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes
26. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS
27. Farnesyltransferase inhibitor causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
28. A peptidomimetic inhibitor of farnesyl:Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
29. K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
30. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
31. Post-translational modifications of p21rho proteins
32. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
33. The role of RhoB in the response to farnesyltransferase inhibitors defined by targeted gene disruption
34. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
35. The farnesyl transferase inhibitor SCH66336 induces cell cycle changes in sensitive human tumor cell lines and prevents the farnesylation of the centromere associated proteins CENP-E and CENP-F
36. Centromeres: Getting a grip of chromosomes
37. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
38. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects
39. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
40. Mouse mammary tumor virus-Ki-ras B transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:Protein transferase inhibitor
41. Concepts in Ras-directed therapy
42. Guanosine triphosphatase stimulation of oncogenic Ras mutants
43. The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2Å resolution ternary complex structures
44. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
45. Yeast protein farnesyltransferase. pK(a)s of peptide substrates bound as zinc thiolates
46. Farnesyl protein transferase: Identification of K164α and Y300β as catalytic residues by mutagenesis and kinetic studies
47. Mutational analysis of α-subunit of protein farnesyltransferase
48. Mutational analysis of conserved residues of the β-subunit of human farnesyl:Protein transferase
49. Co-crystal structure of mammalian protein farnesyltransferase complexed with a farnesyl diphosphate substrate
50. Tricyclic farnesyl protein transferase inhibitors: Crystallographic and calorimetric studies of structure-activity relationships
51. Inhibitor of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068
52. Synthesis and evaluation of hydroxyproline-derived isoprenyltransferase inhibitors
53. Probing the hydrophobic pocket of farnesyltransferase: Aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors
54. Geranylgeranyl-transferase I of Candida albicans: Null mutants or enzyme inhibitors produce unexpected phenotypes
55. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase
56. 2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyl transferase
57. N-Arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity
58. Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase
59. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase
60. Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferase
61. Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity
62. Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy
63. Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]- cyclohepta[1,2-b]pyridin-11-y1)piperidine as inhibitors of farnesyl protein transferase
64. Identification of pharmacokinetically stable 3,10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities
65. Design, synthesis and evaluation of novel modular bisubstrate analogue inhibitors of farnesyltransferase
66. Novel farnesol and geranylgeraniol analogues: A potential new class of anticancer agents directed against protein prenylation
67. Efficient syntheses, human and yeast farnesyl-protein transferase inhibitory activities of chaetomellic acids and analogues
68. 2 bound to farnesyl-protein transferase
69. RPR 130401, a non-peptidomimetic farnesyltransferase inhibitor with in vivo activity